{"contentid": 488080, "importid": NaN, "name": "GSK in out-licensing deal with Boston Pharmaceuticals", "introduction": "UK pharma major GlaxoSmithKline will out-license and option programs to Boston Pharmaceuticals under a newly-announced agreement.", "content": "<p>UK pharma major GlaxoSmithKline (LSE: GSK) will out-license and option programs to Boston Pharmaceuticals (NYSE: BSX) under a newly-announced agreement.</p>\n<p>Boston will become a preferred GSK partner for select pre-Phase II programs. This new agreement builds on the relationship established in 2018 with the US biopharma&rsquo;s acquisition of five programs from the London-based company.</p>\n<p><span class=\"pullQuote\">\"This agreement makes strong strategic sense as it helps us assess the potential of multiple early-stage programs and focus on progressing our own internal assets\"</span>Initially, GSK will out-license and option two programs to Boston, the first being GSK3903371, a monoclonal antibody targeting the interleukin-1 receptor accessory protein, a tumor-associated antigen driving tumor growth and immunosuppression.</p>\n<p>The second is GSK3502421, an orally available, small molecule inhibitor for potential neurological disorders that targets receptor interacting serine/threonine kinase 1, a key component of the TNF-driven inflammation and necroptosis pathway.</p>\n<p>John Lepore, senior vice president, research of GSK, said: &ldquo;We are pleased to further strengthen our relationship with Boston Pharmaceuticals as they continue to help us translate great science into medicines.</p>\n<p>&ldquo;This agreement makes strong strategic sense as it helps us assess the potential of multiple early-stage programs and focus on progressing our own internal assets, while maintaining pipeline optionality for the future.&rdquo;</p>\n<p>Under the agreement, Boston will be responsible for further development of select programs through proof-of-concept (PoC).</p>\n<p>Following the completion of PoC studies, GSK will have the option to reacquire each program under pre-agreed terms for subsequent development and worldwide commercialization.</p>\n<p>If GSK exercises its repurchase option, Boston will receive a one-time payment, as well as be eligible for approval and sales milestones and royalties.</p>\n<p>In the event GSK chooses not to reacquire a program, Boston may continue development and potential commercialization of the program. GSK will then be eligible to receive milestones and royalty payments.</p>\n<p>&nbsp;</p>\n<p>&nbsp;</p>", "date": "2021-03-18 15:44:00", "meta_title": NaN, "meta_keywords": "Boston, programs, agreement, Pharmaceuticals, option, out-license, potential, deal, out-licensing, GlaxoSmithKline, newly-announced, major, pharma, strong", "meta_description": "UK pharma major GlaxoSmithKline will out-license and option programs to Boston Pharmaceuticals under a newly-announced agreement.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-18 15:16:33", "updated": "2021-03-18 15:46:31", "access": NaN, "url": "https://www.thepharmaletter.com/article/gsk-in-out-licensing-deal-with-boston-pharmaceuticals", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "glaxo_gsk_glaxosmithkline_big.jpg", "image2id": "glaxo_gsk_glaxosmithkline_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Neurological, Oncology", "topic_tag": "Deals, Licensing, Research", "geography_tag": "UK, USA", "company_tag": "Boston Pharmaceuticals, GlaxoSmithKline", "drug_tag": "GSK3502421, GSK3903371", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-18 15:44:00"}